Our Science
2022-09-29 17:55
The DNA/RNA nanostructure-based systems hold promise to revolutionize the field of intelligent drug delivery for cancer/metabolic disease therapy. Our multivalent nanocarriers are predesigned DNA/RNA structures that can be integrated with a variety of therapeutic agents (small molecular drugs and biological macromolecules), targeting moieties and structural controlling components. The prominent feature enables us to design and construct versatile DNA/RNA nanomaterials with tissue/cell-specific targeting and controllable drug release for disease treatment.
Our R&D Team
Our team focuses on the research of the design and functionalization of self-assembled nucleic acid nanomaterials. They employ DNA/RNA nanostructures and nanomachines as intelligent drug carriers and realized efficient delivery of various therapeutics, eliciting the potent therapeutic effects, including effective inhibition of tumor growth in several animal models. In recent years, our team has published > 100 articles in top journals (such as Nature Materials, Nature Biotechnology, Nature Communications etc.) and > 10 patents (Chinese and PCT patents). Their work on precise occlusion therapy of tumor blood vessels using DNA nanorobots (Nat. Biotechnol., 2018,36,258) was selected as the top ten scientific advances in China in 2018. Their another work on DNA nanodevice vaccine for cancer immunotherapy (Nat. Mater., 2021,20,421) was listed as the leading technology of "Science and Innovation of China" released by China Association for Science and Technology in 2020. In future, they will focus on the development of biomolecule-based theranostic platforms.
Representative publications
1. A DNA nanodevice-based vaccine for cancer immunotherapy. Nat. Mater. 2021,20,421.
2. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat. Biotechnol. 2018,36,258.
3. A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis. Nat. Commun. 2021,12,358.
4. A Tubular DNA Nanodevice as a siRNA/Chemo-Drug Co-delivery Vehicle for Combined Cancer Therapy. Angew. Chem. Int. Ed. 2021,60,2594.
5. A Tailored DNA Nanoplatform for Synergistic RNAi-/Chemotherapy of Multidrug-Resistant Tumors. Angew. Chem. Int. Ed. 2018,57,15486.
![邮箱：info@dnanotech.bio](javascript:Site.hoverQrCode("//29954287.s21i.faiusr.com/2/ABUIABACGAAgq_fVmQYoovyv0gMwggI4ggI.jpg",this,{"tips":"请使用微信扫一扫"});){kind=link}